Current Clinical Studies

Use the links to the right to view more information about clinical studies by year.

Psoriasis
Sponsor:Astellas Pharma Inc
APPLES: A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitisof ILV-095 Administered Subcutaneously to Subjects With Psoriasis
June 2010 to Present

Psoriasis
Sponsor: Wyeth
A Single Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of ILV-095 Administered Subcutaneously to Subjects With Psoriasis
April 2010 to Present

Healthy Volunteer Program
Sponsor: Eli Lilly & Co.
Biomarker Study of the Smoothened Pathway in Healthy Volunteers
April 2010 to May 2010

Atopic Dermatitis
Sponsor: Novartis
A Prospective 10 Year Observational Registry of Pediatric Subjects (Age Greater Than or Equal to Two to Age Less Than or Equal to 17 Years) With Atopic Dermatitis Who Have Used Pimecrolimus 1% Cream (PEER Registry)
March 2010 to Present

Asthma
Sponsor: GlaxoSmithKline
A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects With Asthma
March 2010 to Present

COPD
Sponsor: Forest Laboratories
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the 2 Aclidinium Bromide Dose
March 2010 to Present

Psoriasis
Sponsor: Amgen, Inc.
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adding Methotrexate to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
February 2010 to Present

Psoriatic Arthritis
Sponsor: Centocor, Inc
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
February 2010 to Present

Acne
Sponsor: Stiefel, a GSK company
A Phase III, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Acne Vulgaris
October 2009 to Present

Acne
Sponsor: Cipher Pharmaceuticals
A Double-Blind, Randomized, Phase III, Parallel Group Study Evaluating the Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne
October 2009 to Present

Obesity
Sponsor: Eli Lilly and Company
A Phase 2 Weight Loss Efficacy Study in Overweight/Obese Men and Women
October 2009 to May 2010

Actinic Keratoses
Sponsor: Peplin Operations
A 12 Month, Long-term Follow-up Study of Patients With Actinic Keratosis on the Head (Face or Scalp) Who Have Completed Day 57 in Studies PEP005-016 or PEP005-025
August 2009 to Present

Actinic Keratoses
Sponsor: Peplin Operations
A Phase III Multi-center, Randomized, Parallel Group, Double-blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of XXXX in Patients with Actinic Keratoses on Non-head Locations
July 2009 to Present

Herpes Zoster
Sponsor: Inhibitex
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Comparative Study of FV-100 vs. Valacyclovir in Patients With Herpes Zoster
June 2009 to Present

Actinic Keratoses
Sponsor: Peplin Operations
A Phase III Multi-center, Randomized, Parallel Group, Double-blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of XXXX In Patients With Actinic Keratoses ON the Head (Face or Scalp)
June 2009 to May 2010

Actinic Keratoses
Sponsor: Peplin Operatons
A Phase III Multi-center, Open-label Study to Evaluate the Safety and Efficacy of XXXX in Patients With Actinic Keratoses on Non-head Locations (Trunk and Extremities)
June 2009 to May 2010

Psoriasis
Sponsor: Abbott Laboratories
A 10-Year, Post-marketing, Observational Study of HUMIRA® (Adalimumab) in Patients With Chronic Plaque Psoriasis (Ps) (ESPRIT Registry)
November 2008 to Present

Psoriasis
Sponsor: Novo Nordisk
A Randomized, Double-blind, Placebo-Controlled, Single and Multiple dose, Dose-Escalation Trial of XXXXX in Psoriatic Subjects, Followed by an Expansion Phase.
October 2008 to Present

Psoriasis
Sponsor: Centocor Ortho Biotech Services, LLC.
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics (PSOLAR Registry)
May 2008 to Present

Psoriasis
Sponsor: Abbott Laboratories
A Phase III Multicenter, Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceding Psoriasis Study With XXXXX (M016)
March 2008 to Present

Arthritis with Cardiovascular Disease
Sponsor: Pfizer
A Randomized, Double Blind, Parallel-Group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen.
December 2006 to Present

Psoriasis
Sponsor: Amgen, Inc.
Observational Post-Marketing Safety Surveillance Registry of Enbrel (Etanercept) for Treatment of Psoriasis. (OBSERVE)
July 2006 to Present

Psoriasis
Sponsor: Centocor, Inc.
A Phase III Trial Evaluating the Efficacy and Safety of XXXXX in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis. (T09)
January 2006 to Present

Psoriasis
Sponsor: Centocor, Inc.
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-Type Psoriasis. (T08)
January 2006 to Present